Hi all,
I just received this email an hour ago...assume others got same too. Wilsons hold faith! Maybe someone can post the full 4 page report.

Wilsons Equity Research Report

Antisense Therapeutics Limited (ANP) | Europe a go!
Pharmaceuticals TP $0.57 | Overweight
Dr Melissa Benson | Dr Shane Storey

We maintain our OVERWEIGHT recommendation on Antisense Therapeutics (ANP) and moderate our risked PT to $0.57 per share owing to equity dilution. Antisense have now received a final positive opinion from EMA on their Phase IIb/III trial in non-ambulant DMD with ATL1102 and have their Clinical Trial Applications currently under review by the relevant European competent authorities to get the trial underway. This trial is the only remaining hurdle to European market access for ATL1102 (WILSe: FY26 EU launch, $630M peak sales). There continue to be plans to harmonise EU and US market access with a single trial, which we view as a possibility given the high unmet clinical need in DMD, positive efficacy data thus far, and FDA precedents in other rare indications (i.e. Radicava® in ALS). Antisense now have capital to get their pivotal EU study underway. Full Report here